The Naproxen Theory: Researchers Poke Holes In Merck Vioxx Defense
This article was originally published in The Tan Sheet
Executive Summary
Naproxen's limited cardioprotective effect relative to aspirin makes it an inadequate explanation for Merck's delay in recalling Vioxx from the market, according to Gurkirpal Singh, MD, Stanford University